ClinicalOpportunity Target hospitals and spine centers evaluating motion-preserving alternatives to fusion for degenerative spondylolisthesis. Position LimiFlex as a disruptive, motion-friendly option that could reduce invasiveness, costs, and recovery times in eligible patient populations.

PMAPreparation Engage regulatory and KOL networks ahead of FDA PMA submission by coordinating early access programs or post-market surveillance partnerships to build real-world evidence and accelerate adoption post-approval.

StrategicPartners Leverage relationships with major spine device distributors and healthcare systems to facilitate trials, training, and deployment of the DST solution in targeted regions, aligning with centers of excellence and high-volume spine programs.

ClinicalEvidence Highlight IDE trial data and ongoing pivotal study progress to clinical stakeholders; develop concise value propositions around reduced cost of care and preserved spinal motion to support payer conversations and coverage potential.

MarketVisibility Increase presence at major spine symposia and leverage digital channels to showcase LimiFlex outcomes, build brand awareness among surgeons specializing in minimally invasive and motion-preserving techniques, and drive inbound inquiries from early-adopter centers.